Stevanato Group S.p.A.
STVN
ISIN IT0005452658 / Valor 112611283
Stevanato Group S.p.A.
UMushroom community rating:
About company
Stevanato Group S.p.A., headquartered in Piombino Dese, Padua, Italy, is a global leader in the pharmaceutical packaging and drug delivery systems sector, with a focus on the production of high-quality glass and plastic components. The company's origins trace back to the establishment of Soffieria Stella near Venice, specializing in glass bottle production, before moving to Piombino Dese in 1959. Over the years, Stevanato Group has expanded its expertise and product offerings through strategic acquisitions and internal development. It acquired Balda, enhancing its capabilities in plastic development for diagnostic consumables, drug delivery systems, and medical components. The acquisition of Optrel furthered its competencies in the manufacture of inspection machines for glass containers in the pharmaceutical industry. Stevanato Group has also established a presence in the United States with its Technology Excellence Center in Boston, Massachusetts, aimed at providing integrated analytical services for drug development and commercialization. The company's international footprint was further expanded with the addition of Medical Glass in Slovakia. Stevanato Group's product portfolio includes high-speed, high-precision glass forming lines, EZ-fill® ready-to-fill sterilized syringes, vials, and cartridges, showcasing its commitment to supporting the pharmaceutical industry's needs for reliable and innovative packaging solutions.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (15.11.2025):
Stevanato Group S.p.A.'s Q3 2025 results showcased robust performance with €303.2 million in revenue, marking a 9% year-over-year increase. The report highlights record levels in high-value solutions and improved margins across key segments, while the company maintains its fiscal 2025 guidance and demonstrates strong operational cash flow.
Revenue Growth
The firm achieved a 9% revenue growth (11% on a constant currency basis) in Q3 2025, with high-value solutions reaching a record €147.9 million, representing 49% of total revenue. Notably, the BDS segment grew by 14%, driven by strong demand for products like the high-performance Nexa® syringes.
Margin and Profitability Improvements
Gross profit margin increased by 240 basis points to 29.2%, complemented by a 260 basis point improvement in operating profit margin (up to 17.4%). Adjusted EBITDA margin also improved by 280 basis points to 25.7%, underpinned by favorable product mix and operational efficiencies.
Segment Performance
The Biopharmaceutical and Diagnostic Solutions (BDS) segment delivered solid growth with revenue of €266.7 million, while the Engineering segment experienced a decline, with revenue dropping 19% to €36.4 million, reflecting challenges in its legacy projects and lower new work volume.
Earnings, Cash Flow, and Guidance
In Q3 2025, diluted earnings per share were €0.13 (adjusted €0.14), and net profit reached €36.1 million (adjusted €38.5 million). The company reported strong cash flow from operations of €47.2 million and maintained its fiscal 2025 guidance, expecting full-year revenue between €1.160 billion and €1.190 billion, along with robust EBITDA and EPS targets.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1029 M
Market cap (USD)
124,430
Daily traded volume (Shares)
21.68 / 20.75
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
